George G Netto

List of Publications by Year
in descending order

286 papers	20,980 citations	15504 65 h-index	12597 132 g-index
301 all docs	301 docs citations	301 times ranked	27057 citing authors

#	Article	IF	Citations
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
2	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	7.1	1,202
3	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
4	UALCAN: An update to the integrated cancer data analysis platform. Neoplasia, 2022, 25, 18-27.	5.3	666
5	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	3.8	423
6	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget, 2011, 2, 627-637.	1.8	383
7	A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions. American Journal of Surgical Pathology, 2010, 34, 1395-1406.	3.7	379
8	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 6563-6573.	7.0	309
9	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
10	Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2014, 20, 890-903.	7.0	275
11	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.8	250
12	TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Research, 2013, 73, 7162-7167.	0.9	214
13	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organsâ€"Part A: Renal, Penile, and Testicular Tumours. European Urology, 2022, 82, 458-468.	1.9	212
14	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 157-165.	1.9	206
15	ERG gene rearrangements are common in prostatic small cell carcinomas. Modern Pathology, 2011, 24, 820-828.	5.5	191
16	Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU International, 2012, 109, 1716-1726.	2.5	187
17	Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers. American Journal of Surgical Pathology, 2010, 34, 1295-1303.	3.7	181
18	¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1003-1010.	5.0	180

#	Article	IF	Citations
19	TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. American Journal of Surgical Pathology, 2016, 40, 723-737.	3.7	168
20	Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics, 2013, 45, 1428-1430.	21.4	164
21	Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service. American Journal of Surgical Pathology, 2013, 37, 1150-1163.	3.7	159
22	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	3.7	154
23	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
24	Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model. Cancer Research, 2009, 69, 4309-4318.	0.9	140
25	Nonâ€invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathology International, 2010, 60, 1-8.	1.3	140
26	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
27	Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern Pathology, 2014, 27, 875-886.	5.5	136
28	Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas. American Journal of Surgical Pathology, 2011, 35, 1014-1020.	3.7	135
29	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoImmunology, 2016, 5, e1134412.	4.6	135
30	PD-L1 Expression Heterogeneity in Nonâ€“Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 2018, 13, 1113-1120.	1.1	135
31	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Antiâ€“PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 726-733.	3.4	133
32	RECURRENT PRIMARY SCLEROSING CHOLANGITIS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 66, 1300-1306.	1.0	133
33	Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Modern Pathology, 2012, 25, 1543-1549.	5.5	124
34	PAX8 (+)/p63 (â˜) Immunostaining Pattern in Renal Collecting Duct Carcinoma (CDC). American Journal of Surgical Pathology, 2010, 34, 965-969.	3.7	123
35	Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ TÂCells in Urothelial Carcinoma. Urology, 2015, 85, 703.e1-703.e6.	1.0	122
36	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	3.8	119

#	Article	IF	Citations
37	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	6.0	118
38	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
39	Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?. Nature Reviews Urology, 2012, 9, 41-51.	3.8	113
40	Molecular Confirmation of t(6;11)(p21;q12) Renal Cell Carcinoma in Archival Paraffin-embedded Material Using a Break-apart TFEB FISH Assay Expands its Clinicopathologic Spectrum. American Journal of Surgical Pathology, 2012, 36, 1516-1526.	3.7	112
41	Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World Journal of Urology, 2013, 31, 861-867.	2.2	110
42	TFEB-amplified Renal Cell Carcinomas. American Journal of Surgical Pathology, 2016, 40, 1484-1495.	3.7	109
43	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5.5	106
44	Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy. Journal of Urology, 2015, 193, 36-40.	0.4	105
45	High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling. Clinical Cancer Research, 2018, 24, 4309-4318.	7.0	105
46	The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation, 2003, 76, 1583-1588.	1.0	101
47	An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer. Cancer Research, 2011, 71, 3812-3821.	0.9	101
48	Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations. American Journal of Surgical Pathology, 2018, 42, 1166-1181.	3.7	98
49	Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases. American Journal of Surgical Pathology, 2008, 32, 461-467.	3.7	95
50	Reâ€evaluation of 33 â€˜unclassifiedâ€™ eosinophilic renal cell carcinomas in young patients. Histopathology, 2018, 72, 588-600.	2.9	92
51	t(6;11) Renal Cell Carcinoma (RCC). American Journal of Surgical Pathology, 2014, 38, 604-614.	3.7	91
52	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget, 2017, 8, 90123-90131.	1.8	89
53	Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma. American Journal of Surgical Pathology, 2006, 30, 1184-1188.	3.7	87
54	VCL-ALK Renal Cell Carcinoma in Children With Sickle-cell Trait. American Journal of Surgical Pathology, 2014, 38, 858-863.	3.7	84

#	Article	IF	Citations
55	Gut Microbiotaâ€“Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling. Cancer Research, 2021, 81, 4014-4026.	0.9	83
56	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Oncotarget, 2015, 6, 29860-29876.	1.8	83
57	Malabsorption Due to Cholecystokinin Deficiency in a Patient with Autoimmune Polyglandular Syndrome Type I. New England Journal of Medicine, 2001, 344, 270-274.	27.0	82
58	Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1. Transplantation, 2002, 74, 1090-1095.	1.0	82
59	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	2.9	82
60	GATA-3 Expression in Trophoblastic Tissues. American Journal of Surgical Pathology, 2015, 39, 101-108.	3.7	80
61	Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate, 2008, 68, 766-772.	2.3	78
62	YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. Cancer Research, 2018, 78, 168-181.	0.9	77
63	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Nonâ€“Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. American Journal of Surgical Pathology, 2018, 42, 1384-1389.	3.7	77
64	Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas. American Journal of Surgical Pathology, 2011, 35, 1549-1556.	3.7	73
65	Distinctive Immunohistochemical Profile of Penile Intraepithelial Lesions. American Journal of Surgical Pathology, 2011, 35, 553-562.	3.7	69
66	Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. American Journal of Surgical Pathology, 2009, 33, 1103-1106.	3.7	67
67	GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Human Pathology, 2012, 43, 2033-2040.	2.0	67
68	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	1.8	67
69	Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer, 2010, 116, 5517-5526.	4.1	66
70	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2010, 16, 3057-3066.	7.0	66
71	Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings. American Journal of Surgical Pathology, 2011, 35, 1351-1355.	3.7	66
72	High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. Journal of Hematology and Oncology, 2014, 7, 47.	17.0	66

#	Article	IF	Citations
73	Low-Grade Papillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of a Postâ€“World Health Organization/International Society of Urological Pathology Classification Cohort From a Single Academic Center. Archives of Pathology and Laboratory Medicine, 2010, 134, 1160-1163.	2.5	65
74	Papillary Renal Cell Carcinoma With Low-grade Spindle Cell Foci. American Journal of Surgical Pathology, 2008, 32, 1353-1359.	3.7	64
75	Diagnostic potential of <scp>TERT</scp> promoter and <scp>FGFR</scp>3 mutations in urinary cellâ€free <scp>DNA</scp> in upper tract urothelial carcinoma. Cancer Science, 2019, 110, 1771-1779.	3.9	63
76	Estrogen Receptor Alpha Prevents Bladder Cancer Development via INPP4B inhibited Akt Pathway in vitro and in vivo. Oncotarget, 2014, 5, 7917-7935.	1.8	63
77	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clinical Cancer Research, 2017, 23, 4693-4703.	7.0	62
78	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9.	16.8	62
79	Pretransplant MELD Score As a Predictor of Outcome After Liver Transplantation for Chronic Hepatitis C. American Journal of Transplantation, 2003, 3, 626-630.	4.7	61
80	Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Human Pathology, 2014, 45, 1130-1138.	2.0	61
81	Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial. Urology, 2011, 77, 1155-1160.	1.0	59
82	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clinical Cancer Research, 2017, 23, 3003-3011.	7.0	59
83	Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Human Pathology, 2017, 59, 55-61.	2.0	58
84	PAX2(â^)/PAX8(â^)/Inhibin A(+) Immunoprofile in Hemangioblastoma. American Journal of Surgical Pathology, 2011, 35, 262-267.	3.7	57
85	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2â€“ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
86	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	7.0	56
87	Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunology Research, 2017, 5, 594-603.	3.4	54
88	Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation ? a clinical and histological examination. Clinical Transplantation, 2006, 20, 695-705.	1.6	53
89	Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Oncotarget, 2015, 6, 1582-1593.	1.8	52
90	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 359-365.	5.5	51

#	Article	IF	Citations
91	Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 428-433.	1.6	51
92	Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use. Cancer Prevention Research, 2015, 8, 208-221.	1.5	51
93	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Molecular Cancer Research, 2018, 16, 1125-1137.	3.4	51
94	Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget, 2017, 8, 91199-91208.	1.8	51
95	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. Neoplasia, 2018, 20, 894-904.	5.3	50
96	Expression of programmed cell death ligand 1 in nonâ€“small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Cancer Cytopathology, 2019, 127, 52-61.	2.4	49
97	TMPRSS2â€“ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Modern Pathology, 2009, 22, 1415-1422.	5.5	48
98	Diagnostic Use of PAX8, CAIX, TTF-1, and TGB in Metastatic Renal Cell Carcinoma of the Thyroid. American Journal of Surgical Pathology, 2011, 35, 757-761.	3.7	48
99	Chromophobe Renal Cell Carcinoma: Multiphase MDCT Enhancement Patterns and Morphologic Features. American Journal of Roentgenology, 2013, 201, 1268-1276.	2.2	48
100	GSTP1Promoter Methylation is Associated with Recurrence in Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 1542-1548.	0.4	48
101	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5390.	4.1	48
102	Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Modern Pathology, 2008, 21, 979-991.	5.5	47
103	PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 525-528.	1.6	47
104	High Prevalence of Screen Detected Prostate Cancer in West Africans: Implications for Racial Disparity of Prostate Cancer. Journal of Urology, 2014, 192, 730-736.	0.4	46
105	GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Human Pathology, 2017, 64, 83-90.	2.0	46
106	Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells. Science Translational Medicine, 2020, 12, .	12.4	46
107	Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology, 2010, 42, 384-394.	0.6	45
108	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Modern Pathology, 2019, 32, 1544-1550.	5.5	45

#	Article	IF	Citations
109	Human papillomavirus infection and immunohistochemical p16INK4a expression as predictors of outcome in penile squamous cell carcinomas. Human Pathology, 2015, 46, 532-540.	2.0	43
110	Primary Renal Sclerosing Epithelioid Fibrosarcoma. American Journal of Surgical Pathology, 2015, 39, 365-373.	3.7	43
111	Utility of uroplakin II expression as a marker of urothelial carcinoma. Human Pathology, 2015, 46, 58-64.	2.0	43
112	Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. Archives of Pathology and Laboratory Medicine, 2012, 136, 372-390.	2.5	42
113	The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. Human Pathology, 2013, 44, 2690-2695.	2.0	42
114	Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS ONE, 2015, 10, e0131245.	2.5	42
115	Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. Molecular Carcinogenesis, 2014, 53, 314-324.	2.7	41
116	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2021, 79, 364-371.	1.9	41
117	Immunohistochemical Analysis of SMARCB1/INI-1 Expression in Collecting Duct Carcinoma. Urology, 2011, 78, 474.e1-474.e5.	1.0	40
118	Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biology and Therapy, 2016, 17, 1188-1196.	3.4	40
119	Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Human Pathology, 2015, 46, 1951-1955.	2.0	39
120	Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Human Pathology, 2016, 47, 20-25.	2.0	39
121	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	2.9	39
122	Topoisomerase II Î± Status in Renal Medullary Carcinoma: Immuno-Expression and Gene Copy Alterations of a Potential Target of Therapy. Journal of Urology, 2009, 182, 735-740.	0.4	38
123	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 427-434.	2.8	38
124	Distinguishing Prostatic From Colorectal Adenocarcinoma on Biopsy Samples: The Role of Morphology and Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2007, 131, 599-603.	2.5	37
125	Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle, 2013, 12, 1058-1070.	2.6	36
126	AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nature Communications, 2017, 8, 142.	12.8	36

#	Article	IF	Citations
127	The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.0	35
128	Pathological characteristics and radiographic correlates of complex renal cysts. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1010-1016.	1.6	35
129	PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate, 2015, 75, 1610-1619.	2.3	35
130	Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. British Journal of Cancer, 2018, 118, 213-223.	6.4	35
131	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 204.e1-204.e7.	1.6	34
132	Frequent BRAF V600E Mutations in Metanephric Stromal Tumor. American Journal of Surgical Pathology, 2016, 40, 719-722.	3.7	34
133	Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. Annals of Surgical Oncology, 2016, 23, 2715-2722.	1.5	34
134	High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Modern Pathology, 2016, 29, 511-515.	5.5	34
135	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	329.8	33
136	Nuclear Factor-Î°B Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling. Molecular Cancer Therapeutics, 2018, 17, 1303-1314.	4.1	33
137	Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 349-356.	2.8	33
138	Combining routine morphology, p16INK4a immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: A tissue microarray study using classifier performance analyses. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 171-177.	1.6	32
139	An introduction to the <scp>WHO</scp> 5th edition 2022 classification of testicular tumours. Histopathology, 2022, 81, 459-466.	2.9	32
140	Reduced Glucocorticoid Receptor Expression Predicts Bladder Tumor Recurrence and Progression. American Journal of Clinical Pathology, 2014, 142, 157-164.	0.7	31
141	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using nextâ€generation sequencing. Cancer Cytopathology, 2016, 124, 744-753.	2.4	31
142	The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. Human Pathology, 2016, 54, 184-188.	2.0	31
143	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Human Pathology, 2016, 53, 8-13.	2.0	31
144	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	3.7	31

#	Article	IF	Citations
145	Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 423-429.	2.8	30
146	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research, 2016, 22, 448-458.	7.0	29
147	Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 761-767.	2.8	29
148	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Human Pathology, 2019, 85, 1-9.	2.0	28
149	Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. PLoS ONE, 2016, 11, e0146302.	2.5	27
150	Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. Molecular Carcinogenesis, 2016, 55, 161-169.	2.7	27
151	Clinical Applications of Recent Molecular Advances in Urologic Malignancies. Advances in Anatomic Pathology, 2013, 20, 175-203.	4.3	26
152	ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. Oncotarget, 2016, 7, 53599-53610.	1.8	26
153	For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 345-350.	2.8	26
154	TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. Modern Pathology, 2021, 34, 842-850.	5.5	26
155	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. Oncotarget, 2018, 9, 30465-30471.	1.8	26
156	MicroRNA expression profiling of Xp11 renal cell carcinoma. Human Pathology, 2017, 67, 18-29.	2.0	25
157	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate, 2018, 78, 1311-1320.	2.3	25
158	Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Frontiers in Oncology, 2020, 10, 755.	2.8	25
159	Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)â€activated prodrug in murine xenograft models of human cancer. Prostate, 2014, 74, 1308-1319.	2.3	24
160	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Human Pathology, 2014, 45, 2233-2239.	2.0	24
161	Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. BJU International, 2016, 118, 112-117.	2.5	24
162	ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling. Endocrine Connections, 2018, 7, 1397-1408.	1.9	24

#	Article	IF	Citations
163	Molecular Diagnostics in Urologic Malignancies: A Work in Progress. Archives of Pathology and Laboratory Medicine, 2011, 135, 610-621.	2.5	24
164	Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment. Clinical Cancer Research, 2010, 16, 5908-5913.	7.0	23
165	Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. Human Pathology, 2013, 44, 2668-2676.	2.0	23
166	Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Histopathology, 2014, 64, 863-871.	2.9	23
167	Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Research, 2015, 75, 4322-4334.	0.9	23
168	PD-L1 expression in nonâ€“small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Human Pathology, 2019, 90, 54-59.	2.0	23
169	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
170	FOXO1 as a tumor suppressor inactivated via AR/ERÎ² signals in urothelial cells. Endocrine-Related Cancer, 2020, 27, 231-244.	3.1	23
171	Interobserver Agreement in Hepatitis C Grading and Staging and in the Banff Grading Schema for Acute Cellular Rejection: The â€œHepatitis C 3â€•Multi-Institutional Trial Experience. Archives of Pathology and Laboratory Medicine, 2006, 130, 1157-1162.	2.5	23
172	Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra. Human Pathology, 2013, 44, 2760-2767.	2.0	22
173	Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. Human Pathology, 2014, 45, 244-248.	2.0	22
174	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. American Journal of Clinical Pathology, 2016, 145, 696-702.	0.7	22
175	A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer. Journal of Urology, 2016, 195, 880-885.	0.4	22
176	Diagnostic Molecular Pathology: Current Techniques and Clinical Applications, Part I. Baylor University Medical Center Proceedings, 2003, 16, 379-383.	0.5	21
177	Cadaveric Orthotopic Auxiliary Split Liver Transplantation and Kidney Transplantation: An Alternative for Type 1 Primary Hyperoxaluria. Transplantation, 2005, 80, 421-424.	1.0	21
178	Emerging Bladder Cancer Biomarkers and Targets of Therapy. Urologic Clinics of North America, 2016, 43, 63-76.	1.8	21
179	Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 34.e17-34.e25.	1.6	21
180	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. Translational Oncology, 2019, 12, 1416-1424.	3.7	21

#	Article	IF	Citations
181	<scp>GPNMB</scp> expression identifies <scp>TSC1</scp>/2/<scp>mTOR</scp>â€associated and <scp>MiT</scp> family translocationâ€driven renal neoplasms. Journal of Pathology, 2022, 257, 158-171.	4.5	21
182	High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a postâ€“World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Human Pathology, 2012, 43, 115-120.	2.0	20
183	A comprehensive resequenceâ€analysis of 250â€‰kb region of 8q24.21 in men of African ancestry. Prostate, 2014, 74, 579-589.	2.3	20
184	Tumor immune microenvironment in nonâ€“muscle-invasive urothelial carcinoma of the bladder. Human Pathology, 2019, 89, 24-32.	2.0	20
185	Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy. Advances in Anatomic Pathology, 2020, 27, 36-43.	4.3	20
186	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 680973.	4.8	20
187	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
188	Protection by Cyclosporine A against Normothermic Liver Ischemia-Reperfusion in Pigs. Journal of Surgical Research, 1998, 75, 116-126.	1.6	19
189	Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Human Pathology, 2011, 42, 1799-1803.	2.0	19
190	Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. Urology, 2014, 83, 1444.e1-1444.e6.	1.0	19
191	Sacrococcygeal teratomas: clinico-pathological characteristics and isochromosome 12p status. Modern Pathology, 2014, 27, 562-568.	5.5	19
192	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International, 2016, 2016, 1-12.	1.9	19
193	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. Clinical Genitourinary Cancer, 2016, 14, e515-e520.	1.9	19
194	Pathology Imagebaseâ€”a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	2.9	19
195	GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma. Science Signaling, 2020, 13, .	3.6	19
196	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene, 2020, 39, 4077-4091.	5.9	19
197	TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Modern Pathology, 2022, 35, 376-385.	5.5	19
198	An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget, 2014, 5, 5218-5233.	1.8	19

#	Article	IF	Citations
199	Molecular genetics and genomics progress in urothelial bladder cancer. Seminars in Diagnostic Pathology, 2013, 30, 313-320.	1.5	18
200	Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. Investigative and Clinical Urology, 2017, 58, 20.	2.0	17
201	Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget, 2014, 5, 3350-3361.	1.8	17
202	Detection of low level benzene exposure in supermarket wrappers by urinary muconic acid. Biomarkers, 1999, 4, 106-117.	1.9	16
203	Aggressive recurrent respiratory papillomatosis in a neonate. International Journal of Pediatric Otorhinolaryngology, 2008, 72, 917-920.	1.0	16
204	Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. Human Pathology, 2013, 44, 2323-2330.	2.0	16
205	High Levels of Phosphatase and Tensin Homolog Expression Are Associated With Tumor Progression, Tumor Recurrence, and Systemic Metastases in pT1 Urothelial Carcinoma of the Bladder: A Tissue Microarray Study of 156 Patients Treated by Transurethral Resection. Urology, 2013, 81, 116-122.	1.0	16
206	Biobanking of derivatives from radical retropubic and robotâ€assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate, 2014, 74, 61-69.	2.3	16
207	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. Journal of Molecular Diagnostics, 2017, 19, 475-484.	2.8	16
208	Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Human Pathology, 2013, 44, 612-622.	2.0	15
209	Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection. Histopathology, 2015, 66, 262-269.	2.9	15
210	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 271-280.	2.8	15
211	Iatrogenic pathology of the urinary bladder. Seminars in Diagnostic Pathology, 2018, 35, 218-227.	1.5	15
212	Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 93-102.	2.8	15
213	Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine, 2014, 12, 199.	4.4	14
214	The Utility of an Extensive Postchemotherapy Staging Evaluation in Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer. Urology, 2014, 84, 358-364.	1.0	14
215	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 216-227.	9.6	14
216	Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas. Modern Pathology, 2021, 34, 2055-2063.	5.5	14

#	Article	IF	Citations
217	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. Journal of Clinical Pathology, 2021, 74, 291-299.	2.0	14
218	Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8580-E8582.	7.1	13
219	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS ONE, 2016, 11, e0146189.	2.5	13
220	Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Urology, 2017, 102, 148-158.	1.0	12
221	Characterization of glycineâ€Nâ€acyltransferase like 1 (GLYATL1) in prostate cancer. Prostate, 2019, 79, 1629-1639.	2.3	12
222	Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 21-27.	2.8	12
223	Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 705440.	2.8	12
224	Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 10030.	4.1	12
225	Highâ€fat diet promotes prostate cancer growth through histamine signaling. International Journal of Cancer, 2022, 151, 623-636.	5.1	12
226	INSL3 Expression in Leydig Cell Hyperplasia and Leydig Cell Tumors. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 203-209.	1.2	11
227	Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma. Histopathology, 2020, 76, 423-432.	2.9	11
228	Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer. Cancers, 2021, 13, 975.	3.7	11
229	High prevalence of polyclonal hypergammaâ€globulinemia in adult males in Ghana, Africa. American Journal of Hematology, 2011, 86, 554-558.	4.1	10
230	Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 572-575.	1.6	10
231	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Human Pathology, 2015, 46, 761-766.	2.0	10
232	Urological cancer related to familial syndromes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 192-201.	1.5	10
233	Diagnostic Molecular Pathology: An Increasingly Indispensable Tool for the Practicing Pathologist. Archives of Pathology and Laboratory Medicine, 2006, 130, 1339-1348.	2.5	10
234	Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection. Surgical Pathology Clinics, 2008, 1, 1-41.	1.7	9

#	Article	IF	Citations
235	High-Grade Prostatic Adenocarcinoma Present in a Single Biopsy Core is Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgical Margins at Prostatectomy. Urology, 2012, 79, 863-868.	1.0	9
236	Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. Urology, 2016, 92, 51-56.	1.0	9
237	Clinical, pathologic, and genomic profiles of exceptional responders to antiâ^'PD1 therapy in renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 625-625.	1.6	9
238	<scp>BCG</scp> invokes superior <scp>STING</scp>â€mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. Journal of Pathology, 2022, 256, 223-234.	4.5	9
239	High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. Human Pathology, 2016, 54, 106-112.	2.0	8
240	Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet, The, 2016, 387, 1881-1882.	13.7	8
241	Conventional prostatic adenocarcinoma arising in a multilocular prostatic cystadenoma. Pathology International, 2010, 60, 413-416.	1.3	7
242	Smooth muscle and adenoma-like renal tumor: a previously unreported variant of mixed epithelial stromal tumor or a distinctive renal neoplasm?. Human Pathology, 2015, 46, 894-905.	2.0	7
243	Molecular Updates in Prostate Cancer. Surgical Pathology Clinics, 2015, 8, 561-580.	1.7	7
244	TMPRSS2â€"ERG fusion as a marker of prostatic lineage in smallâ€cell carcinoma. Histopathology, 2010, 57, 633-633.	2.9	6
245	Immunohistology of the Prostate, Bladder, Kidney, and Testis. , 2011, , 593-661.		6
246	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
247	Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 695-701.	2.8	5
248	Well-differentiated neuroendocrine tumors of the lower urinary tract: biologic behavior of a rare entity. Human Pathology, 2021, 109, 53-58.	2.0	5
249	Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from crossâ€sectional data. International Journal of Urology, 2021, 28, 774-776.	1.0	5
250	Molecular Pathology of Urothelial Carcinoma. Surgical Pathology Clinics, 2021, 14, 403-414.	1.7	4
251	Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Modern Pathology, 2021, , .	5.5	4
252	Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1187-1196.	2.8	4

#	Article	IF	Citations
253	The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. American Journal of Translational Research (discontinued), 2020, 12, 3033-3045.	0.0	4
254	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
255	Mesenchymal Tumors of the Prostate. Surgical Pathology Clinics, 2008, 1, 105-128.	1.7	3
256	Molecular Pathology of Bladder Cancer. Surgical Pathology Clinics, 2012, 5, 843-858.	1.7	3
257	Single 15-Min Protocol Yields the Same Cryoablation Size and Margin as the Conventional 10â€“8â€“10-Min Protocol: Results of Kidney and Liver Swine Experiment. CardioVascular and Interventional Radiology, 2018, 41, 1089-1094.	2.0	3
258	Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 969-974.	2.8	3
259	Programmed cell deathâ€ligandâ€‰1 expression in different molecular subtypes of upper tract urothelial carcinoma. International Journal of Urology, 2022, 29, 89-90.	1.0	3
260	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.. Journal of Clinical Oncology, 2015, 33, 336-336.	1.6	3
261	Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.. Journal of Clinical Oncology, 2016, 34, 4526-4526.	1.6	3
262	Fat-Predominant Mixed Epithelial Stromal Tumor (MEST): Report of a Unique Case Mimicking Angiomyolipoma. International Journal of Surgical Pathology, 2008, 16, 73-77.	0.8	2
263	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 1399-1400.	5.5	2
264	A 66-Year-old Man With Prostate-specific Antigen Recurrence and Lung Mass After Radical Prostatectomy. Urology, 2012, 80, 247-249.	1.0	2
265	Activation of Mammalian Target of Rapamycin Signaling Pathway Markers in Minute Adenocarcinoma of the Prostate. Urology, 2013, 82, 1083-1089.	1.0	2
266	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. European Urology Supplements, 2017, 16, 253-271.	0.1	2
267	Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding proteinÂ3 expression. International Journal of Urology, 2019, 26, 678-679.	1.0	2
268	The Ever Changing Landscape of Anatomic Pathology Practice. Advances in Anatomic Pathology, 2020, 27, 1-2.	4.3	2
269	Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.. Journal of Clinical Oncology, 2015, 33, 5059-5059.	1.6	2
270	A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2015, 33, 360-360.	1.6	2

#	Article	IF	Citations
271	Molecular Pathology of Urinary Bladder Cancer. , 2013, , 229-253.		1
272	A Right Atrial Mass: â€œMore Than Meets the Eyeâ€• Journal of Clinical Oncology, 2016, 34, e49-e50.	1.6	1
273	Preparing pathology for the molecular era. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 137-140.	2.8	1
274	Rare case of squamous cell carcinoma arising from tunica vaginalis in a background of chronic hydrocele. Urology Case Reports, 2019, 23, 55-57.	0.3	1
275	Rare MDM2 amplification in a fat-predominant angiomyolipoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 661-666.	2.8	1
276	PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2015, 33, 300-300.	1.6	1
277	Molecular Biomarker Testing in Localized Prostate Cancer: The Critical Role of Pathologists. Archives of Pathology and Laboratory Medicine, 2021, 145, 264-265.	2.5	1
278	Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic. BMJ Open, 2022, 12, e053912.	1.9	1
279	Spindle Cell Sarcoma of the Uterus Harboring MEIS1::NCOA1 Fusion Gene and Mimicking Endometrial Stromal Sarcoma. International Journal of Surgical Pathology, 2023, 31, 227-232.	0.8	1
280	Thyroid transcription factor 1 expression in a case of renal collecting duct carcinomaâ€”Reply. Human Pathology, 2012, 43, 1154.	2.0	0
281	MicroRNAs, promising biomarkers in the diagnosis of Xp11 translocation RCCâ€”reply. Human Pathology, 2017, 68, 206-207.	2.0	0
282	Editorial. Modern Pathology, 2020, 33, 178-178.	5.5	0
283	Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise.. Journal of Clinical Oncology, 2015, 33, 173-173.	1.6	0
284	Genitourinary Tumors. , 2020, , 133-147.		0
285	Editorial Comment: A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 275-276.	1.5	0
286	Renal cell carcinoma presenting with brain metastasis from a 1.6 cm primary tumor. Canadian Journal of Urology, 2013, 20, 6965-7.	0.0	0